Header Logo

Connection

Jeffrey Kordower to Neurons

Back to Details
This is a "connection" page, showing publications Jeffrey Kordower has written about Neurons.
Jeffrey Kordower
Connection Strength
8.366
Neurons
  1. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiol Dis. 2021 01; 148:105184.
    View in: PubMed
    Score: 0.585
  2. Spreading of alpha-synuclein - relevant or epiphenomenon? J Neurochem. 2019 09; 150(5):605-611.
    View in: PubMed
    Score: 0.532
  3. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017 02 15; 525(3):498-512.
    View in: PubMed
    Score: 0.436
  4. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013 Aug; 136(Pt 8):2419-31.
    View in: PubMed
    Score: 0.353
  5. Neuropathology in transplants in Parkinson's disease: implications for disease pathogenesis and the future of cell therapy. Prog Brain Res. 2012; 200:221-41.
    View in: PubMed
    Score: 0.316
  6. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2012 May; 27(6):709-15.
    View in: PubMed
    Score: 0.306
  7. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci. 2011 06; 12(6):359-66.
    View in: PubMed
    Score: 0.303
  8. Transfer of host-derived a synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis. 2011 Sep; 43(3):552-7.
    View in: PubMed
    Score: 0.302
  9. a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
    View in: PubMed
    Score: 0.288
  10. Long-term gonadal hormone treatment and endogenous neurogenesis in the dentate gyrus of the adult female monkey. Exp Neurol. 2010 Jul; 224(1):252-7.
    View in: PubMed
    Score: 0.280
  11. Propagation of host disease to grafted neurons: accumulating evidence. Exp Neurol. 2009 Dec; 220(2):224-5.
    View in: PubMed
    Score: 0.270
  12. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis. 2009 Apr; 34(1):40-50.
    View in: PubMed
    Score: 0.256
  13. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008 Dec 15; 23(16):2303-6.
    View in: PubMed
    Score: 0.256
  14. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiol Dis. 2007 May; 26(2):375-84.
    View in: PubMed
    Score: 0.224
  15. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.209
  16. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol. 2004 Jul 19; 475(2):211-9.
    View in: PubMed
    Score: 0.188
  17. Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery. Mov Disord. 2023 09; 38(9):1728-1736.
    View in: PubMed
    Score: 0.176
  18. GFAP knockout mice have increased levels of GDNF that protect striatal neurons from metabolic and excitotoxic insults. J Comp Neurol. 2003 Jun 30; 461(3):307-16.
    View in: PubMed
    Score: 0.175
  19. Knockout of p75NTR does not alter the viability of striatal neurons following a metabolic or excitotoxic injury. J Mol Neurosci. 2003 Apr; 20(2):93-102.
    View in: PubMed
    Score: 0.172
  20. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 2002 Aug 26; 450(3):203-14.
    View in: PubMed
    Score: 0.165
  21. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002 Feb 04; 443(2):136-53.
    View in: PubMed
    Score: 0.159
  22. In situ proximity labeling identifies Lewy pathology molecular interactions in the human brain. Proc Natl Acad Sci U S A. 2022 02 01; 119(5).
    View in: PubMed
    Score: 0.159
  23. Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
    View in: PubMed
    Score: 0.144
  24. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
    View in: PubMed
    Score: 0.139
  25. Disease Modification Through Trophic Factor Delivery. Methods Mol Biol. 2018; 1780:525-547.
    View in: PubMed
    Score: 0.120
  26. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017 12; 298(Pt B):225-235.
    View in: PubMed
    Score: 0.118
  27. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun. 2017 06 16; 5(1):47.
    View in: PubMed
    Score: 0.115
  28. Targeting a-Synuclein as a therapy for Parkinson's disease: The battle begins. Mov Disord. 2017 02; 32(2):203-207.
    View in: PubMed
    Score: 0.112
  29. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14.
    View in: PubMed
    Score: 0.093
  30. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One. 2011; 6(12):e28032.
    View in: PubMed
    Score: 0.079
  31. Cell transplantation and gene therapy in Parkinson's disease. Mt Sinai J Med. 2011 Jan-Feb; 78(1):126-58.
    View in: PubMed
    Score: 0.074
  32. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem. 2010 Jun; 113(5):1073-91.
    View in: PubMed
    Score: 0.070
  33. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther. 2010 Mar; 18(3):579-87.
    View in: PubMed
    Score: 0.067
  34. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A. 2009 Jul 28; 106(30):12483-8.
    View in: PubMed
    Score: 0.067
  35. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease. Neurotox Res. 2010 Jan; 17(1):66-74.
    View in: PubMed
    Score: 0.067
  36. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
    View in: PubMed
    Score: 0.066
  37. Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Exp Neurol. 2009 Apr; 216(2):342-56.
    View in: PubMed
    Score: 0.064
  38. Future of cell and gene therapies for Parkinson's disease. Ann Neurol. 2008 Dec; 64 Suppl 2:S122-38.
    View in: PubMed
    Score: 0.064
  39. Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure in monkeys. Glia. 2008 Aug 15; 56(11):1199-214.
    View in: PubMed
    Score: 0.062
  40. Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. J Comp Neurol. 2007 Jun 10; 502(5):683-700.
    View in: PubMed
    Score: 0.058
  41. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006 Dec; 60(6):706-15.
    View in: PubMed
    Score: 0.056
  42. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis. 2007 Jan; 25(1):134-49.
    View in: PubMed
    Score: 0.055
  43. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9345-50.
    View in: PubMed
    Score: 0.054
  44. RET expression does not change with age in the substantia nigra pars compacta of rhesus monkeys. Neurobiol Aging. 2006 Jun; 27(6):857-61.
    View in: PubMed
    Score: 0.050
  45. RNA amplification of bromodeoxyuridine labeled newborn neurons in the monkey hippocampus. J Neurosci Methods. 2005 Jun 15; 144(2):197-201.
    View in: PubMed
    Score: 0.049
  46. Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs. Exp Neurol. 2023 10; 368:114509.
    View in: PubMed
    Score: 0.044
  47. Etiology of Parkinson's disease: Genetics and environment revisited. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):13972-4.
    View in: PubMed
    Score: 0.042
  48. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. 2002 Jun 15; 22(12):4942-54.
    View in: PubMed
    Score: 0.041
  49. T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathol. 2020 05; 139(5):855-874.
    View in: PubMed
    Score: 0.035
  50. Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity. Neural Plast. 2019; 2019:6286197.
    View in: PubMed
    Score: 0.033
  51. Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA. Mol Neurobiol. 2018 Nov; 55(11):8728-8737.
    View in: PubMed
    Score: 0.030
  52. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Sci Transl Med. 2016 12 07; 8(368):368ra174.
    View in: PubMed
    Score: 0.028
  53. Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease. Hum Mol Genet. 2015 Sep 15; 24(18):5285-98.
    View in: PubMed
    Score: 0.025
  54. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with a-synucleinopathies. Neurobiol Dis. 2015 Jun; 78:162-71.
    View in: PubMed
    Score: 0.025
  55. Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor a. Cell Rep. 2013 Aug 29; 4(4):724-37.
    View in: PubMed
    Score: 0.022
  56. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis. 2011 Oct; 44(1):38-52.
    View in: PubMed
    Score: 0.019
  57. Decreased alpha-synuclein expression in the aging mouse substantia nigra. Exp Neurol. 2009 Dec; 220(2):359-65.
    View in: PubMed
    Score: 0.017
  58. Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys. Neurobiol Aging. 2010 Jun; 31(6):937-52.
    View in: PubMed
    Score: 0.016
  59. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006 Aug; 60(2):260-4.
    View in: PubMed
    Score: 0.014
  60. Survival and early differentiation of human neural stem cells transplanted in a nonhuman primate model of stroke. J Neurosurg. 2006 Jul; 105(1):96-102.
    View in: PubMed
    Score: 0.013
  61. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.